Wolfgang Bernauer
Research Subjects
Wolfgang Bernauer has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
M. A. Thiel
University of Zürich
4 shared publicationsMatthias Brunner
OMMA Eye Center
4 shared publicationsA. R. von Hochstetter
Pathologie Institut Enge
3 shared publicationsK. M. Rentsch
Institute of Clinical Chemistry, University of Zürich
3 shared publicationsJulia K. Lacoste
ÓMMA Praxis
2 shared publicationsU. M. Langenauer
2 shared publications
Latest Publications
- 10 July 2014
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 252 (9) , 1477-1481
Five-year outcome in immune-mediated scleritis
Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce. The aim of this study was to identify prognostic factors, complications, and therapeutic effects in patients with immune-mediated scleritis. Patients with diagnosis of scleritis and a follow-up time of 5 years were identified. Systemic disease, laboratory investigations, type of scleritis, disease activity, therapy, and complications were recorded. The study design was a retrospective, non-comparative, interventional case series. Systemic disease was identified in 15 (37 %) patients at presentation and in 18 (45 %) after 5 years. Rheumatoid arthritis (15 %), granulomatosis with polyangiitis (7.5 %), and polychondritis (7.5 %) were the most predominant disorders. Persistent scleritis (>5 years) was associated with systemic disease (66 vs. 6 %; p < 0.05) and positive auto-antibodies (48 vs. 23 %; p = 0.18). Control of ocular inflammation was achieved in 38 of 40 (95 %). Prednisone (14 patients) and/or methotrexate (8) were the predominant drugs to control persistent disease. Complications included interstitial keratitis (2), inflammatory astigmatism (2), corneal melt (3), macular edema (6), and severe systemic disease (5). The presence of systemic disease and positive auto-antibodies are associated with persistent scleritis. Immunosuppressive agents allow control of scleritis, but may contribute to severe systemic complications.
- 10 July 2014
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 252 (9) , 1477-1481
Five-year outcome in immune-mediated scleritis
Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce. The aim of this study was to identify prognostic factors, complications, and therapeutic effects in patients with immune-mediated scleritis. Patients with diagnosis of scleritis and a follow-up time of 5 years were identified. Systemic disease, laboratory investigations, type of scleritis, disease activity, therapy, and complications were recorded. The study design was a retrospective, non-comparative, interventional case series. Systemic disease was identified in 15 (37 %) patients at presentation and in 18 (45 %) after 5 years. Rheumatoid arthritis (15 %), granulomatosis with polyangiitis (7.5 %), and polychondritis (7.5 %) were the most predominant disorders. Persistent scleritis (>5 years) was associated with systemic disease (66 vs. 6 %; p < 0.05) and positive auto-antibodies (48 vs. 23 %; p = 0.18). Control of ocular inflammation was achieved in 38 of 40 (95 %). Prednisone (14 patients) and/or methotrexate (8) were the predominant drugs to control persistent disease. Complications included interstitial keratitis (2), inflammatory astigmatism (2), corneal melt (3), macular edema (6), and severe systemic disease (5). The presence of systemic disease and positive auto-antibodies are associated with persistent scleritis. Immunosuppressive agents allow control of scleritis, but may contribute to severe systemic complications.
- 1 January 2013
- Published by Springer Nature
- p. 27-30
Trübe Hornhaut nach Pterygium-Operation
- 1 January 2013
- Published by Springer Nature
- p. 19-22
Granulomatöse Konjunktivitis
- 1 January 2013
- Published by Springer Nature
- p. 15-18
Zunehmend gerötete Augen und Hyperplasie der Bindehaut
- 1 January 2013
- Published by Springer Nature
- p. 15-18
Zunehmend gerötete Augen und Hyperplasie der Bindehaut
- 1 January 2013
- Published by Springer Nature
- p. 137-139
Knirschgeräusche im Auge
- 21 March 2008
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 246 (7) , 975-978
Phosphate concentration in ophthalmic corticoid preparations
Topical preparations, high in phosphate, may cause calcification when used on a damaged corneal surface. The knowledge of the phosphate concentration in medications helps to prevent corneal calcifications. Our study gives an overview of the amount of phosphate contained in ophthalmic corticoid preparations. Samples of 38 commercially available corticoid preparations were tested. The quantification of phosphate was performed using the molybdate method on a Modular P autoanalyzer. 18 of 38 preparations (47%) had a phosphate concentration above physiological levels (>1.45 mmol/l). It varied greatly, and ranged from less than 0.1 mmol/l (18 preparations) to 62.6 mmol/l. The corticoids that were tested included betamethasone sodium phosphate (18.3-35.5 mmol/l), dexamethasone (0.1-17.6 mmol/l), dexamethasone sodium phosphate (<0.1-62.6 mmol/l), fluorometholone (<0.1-22.5 mmol/l), and prednisolone acetate (<0.1-0.5 mmol/l). The phosphate concentration in corticoid-phosphate formulations varies greatly, and is mainly determined by the chosen buffer. The prednisolone acetate preparations showed physiological phosphate concentrations. For a treatment on a damaged corneal surface, preparations with physiological phosphate concentrations should be used.
- 21 March 2008
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 246 (7) , 975-978
Phosphate concentration in ophthalmic corticoid preparations
Topical preparations, high in phosphate, may cause calcification when used on a damaged corneal surface. The knowledge of the phosphate concentration in medications helps to prevent corneal calcifications. Our study gives an overview of the amount of phosphate contained in ophthalmic corticoid preparations. Samples of 38 commercially available corticoid preparations were tested. The quantification of phosphate was performed using the molybdate method on a Modular P autoanalyzer. 18 of 38 preparations (47%) had a phosphate concentration above physiological levels (>1.45 mmol/l). It varied greatly, and ranged from less than 0.1 mmol/l (18 preparations) to 62.6 mmol/l. The corticoids that were tested included betamethasone sodium phosphate (18.3-35.5 mmol/l), dexamethasone (0.1-17.6 mmol/l), dexamethasone sodium phosphate (<0.1-62.6 mmol/l), fluorometholone (<0.1-22.5 mmol/l), and prednisolone acetate (<0.1-0.5 mmol/l). The phosphate concentration in corticoid-phosphate formulations varies greatly, and is mainly determined by the chosen buffer. The prednisolone acetate preparations showed physiological phosphate concentrations. For a treatment on a damaged corneal surface, preparations with physiological phosphate concentrations should be used.
- 26 April 2007
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 224 (4) , 249-251
Phosphate Concentrations in Antiglaucoma Medication
Hintergrund: Die in vielen Tropfpräparaten als Pufferbestandteile enthaltenen Phosphat-Anionen können zu Hornhautverkalkungen Anlass geben. Die Kenntnis der Phosphatkonzentrationen in ophthalmologischen Präparaten ist eine Hilfe bei der Vermeidung dieser gravierenden Komplikation. Zurzeit muss der Phosphatgehalt von den Präparatherstellern nicht deklariert werden, da es sich pharmakologisch nur um einen Hilfsstoff handelt. Unsere Studie untersucht die Phosphatkonzentrationen in Glaukompräparaten. Methode: 21 Präparate wurden untersucht. Zur Messung der Phosphatkonzentration wurde das Modular P-Gerät von Roche Diagnostics eingesetzt. Ergebnisse: 10 von 21 (47 %) Glaukompräparaten wiesen unphysiologische hohe Konzentrationen auf (> 1,45 mmol/l). Konzentrationen über 100 mmol/l wurden bei vier Präparaten gemessen, die den Beta-Blocker Timolol enthalten. Schlussfolgerung: Etwa die Hälfte der in der Schweiz erhältlichen Glaukompräparate sind mit Phosphat gepuffert. Dabei weisen einige Beta-Blocker sehr hohe Phosphat-Konzentrationen auf. Bei kompromittierter Augenoberfläche und epithelialer Keratopathie können diese Präparate die Entwicklung von durchgreifenden Hornhautverkalkungen begünstigen und sollten gemieden werden. Background: Eye drops may contain phosphates as part of their buffer system. In the presence of epithelial keratopathy a high concentration of phosphate favours corneal calcification. To date European legislation does not require a quantitative declaration of the phosphates since buffers are regarded as additives. The knowledge of the phosphate concentration in medications helps to prevent corneal calcifications. Our study gives an overview on the amount of phosphate contained in antiglaucoma drops. Methods: 21 samples of commercially available antiglaucoma drops were tested. The quantification of phosphate was performed using the molybdate method on a Modular P autoanalyzer. Results: 10 of 21 (47 %) glaucoma drops had a phosphate concentration above physiological levels (> 1.45 mmol/L). A concentration higher than 100 mmol/L was found in four preparations that contained timolol. Conclusions: Many antiglaucoma drops contain unphysiological levels of phosphate, very high concentrations are found in some beta-blockers. These preparations have the potential to favour the formation of insoluble crystalline calcium phosphate deposits when used on a damaged corneal surface, and should therefore be avoided.
- 26 April 2007
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 224 (4) , 249-251
Phosphate Concentrations in Antiglaucoma Medication
Hintergrund: Die in vielen Tropfpräparaten als Pufferbestandteile enthaltenen Phosphat-Anionen können zu Hornhautverkalkungen Anlass geben. Die Kenntnis der Phosphatkonzentrationen in ophthalmologischen Präparaten ist eine Hilfe bei der Vermeidung dieser gravierenden Komplikation. Zurzeit muss der Phosphatgehalt von den Präparatherstellern nicht deklariert werden, da es sich pharmakologisch nur um einen Hilfsstoff handelt. Unsere Studie untersucht die Phosphatkonzentrationen in Glaukompräparaten. Methode: 21 Präparate wurden untersucht. Zur Messung der Phosphatkonzentration wurde das Modular P-Gerät von Roche Diagnostics eingesetzt. Ergebnisse: 10 von 21 (47 %) Glaukompräparaten wiesen unphysiologische hohe Konzentrationen auf (> 1,45 mmol/l). Konzentrationen über 100 mmol/l wurden bei vier Präparaten gemessen, die den Beta-Blocker Timolol enthalten. Schlussfolgerung: Etwa die Hälfte der in der Schweiz erhältlichen Glaukompräparate sind mit Phosphat gepuffert. Dabei weisen einige Beta-Blocker sehr hohe Phosphat-Konzentrationen auf. Bei kompromittierter Augenoberfläche und epithelialer Keratopathie können diese Präparate die Entwicklung von durchgreifenden Hornhautverkalkungen begünstigen und sollten gemieden werden. Background: Eye drops may contain phosphates as part of their buffer system. In the presence of epithelial keratopathy a high concentration of phosphate favours corneal calcification. To date European legislation does not require a quantitative declaration of the phosphates since buffers are regarded as additives. The knowledge of the phosphate concentration in medications helps to prevent corneal calcifications. Our study gives an overview on the amount of phosphate contained in antiglaucoma drops. Methods: 21 samples of commercially available antiglaucoma drops were tested. The quantification of phosphate was performed using the molybdate method on a Modular P autoanalyzer. Results: 10 of 21 (47 %) glaucoma drops had a phosphate concentration above physiological levels (> 1.45 mmol/L). A concentration higher than 100 mmol/L was found in four preparations that contained timolol. Conclusions: Many antiglaucoma drops contain unphysiological levels of phosphate, very high concentrations are found in some beta-blockers. These preparations have the potential to favour the formation of insoluble crystalline calcium phosphate deposits when used on a damaged corneal surface, and should therefore be avoided.
- 16 May 2006
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 223 (5) , 353-356
Therapierefraktäre chronische (Kerato-)Conjunctivitis bei Kindern
Hintergrund: Chronische (Kerato-)Conjunctivitiden verursachen eine erhebliche okuläre Morbidität. Durch eine frühzeitige Diagnostik und korrekte Behandlung können strukturelle Schäden der Augenoberfläche und damit auch Sehstörungen vermieden werden. Bei Kindern kommt es nicht selten zu verschleppten Verläufen infolge geringer individueller Erfahrung des behandelnden Arztes, ungewöhnlicher klinischer Manifestationen und der Seltenheit einzelner Krankheitsbilder. Diese Studie untersucht die Probleme, die bei der Diagnostik der chronischen (Kerato-)Conjunctivitis im Kindesalter auftreten. Patienten und Methoden: 48 Patienten, die von niedergelassenen Ophthalmologen zur weiteren Abklärung einer therapierefraktären chronischen Conjunctivitis zugewiesen worden waren, wurden untersucht. Der Altersmeridian lag bei 8,5 Jahren, die mediane Erkrankungsdauer betrug 23 Monate (3 - 118). Durchschnittlich wurden 2,8 Augenärzte konsultiert, bevor die Diagnostik abgeschlossen wurde. Die klinischen Befunde wurden mit einem standardisierten Protokoll erfasst und analysiert. Bei 20 von 48 Patienten wurde die klinische Diagnose durch Laborbefunde bestätigt. Ergebnisse: Bei 33 von 48 Patienten stand der therapierefraktäre Verlauf mit einer ungenügenden Diagnostik in Zusammenhang. Die häufigsten Diagnosen waren „Staphylokokkenproblematik” (n = 21) und „Keratoconjunctivitis vernalis” (n = 12). Am häufigsten wurde die Diagnose einer Infektion mit Molluscum-contagiosum-Virus verpasst (n = 7). Die Conjunctivitis lignosa (n = 2) wurde von 9 Voruntersuchern verkannt. Eine klinisch relevante Hornhautbeteiligung fand sich bei insgesamt 24 Patienten (50 %). Schlussfolgerung: Eine präzise Anamnese und minutiöse Untersuchung der gesamten Augenoberfläche ermöglichen praktisch ausnahmslos eine korrekte diagnostische Einstufung und Therapie von chronisch entzündlichen Oberflächenerkrankungen im Kindesalter. Nach gewissen diagnostischen Schlüsselbefunden wie warzigen Veränderungen am anterioren Lidrand, Collerettes, Follikeln, Papillen und speziellen Stippungsmustern der Hornhaut muss aktiv gesucht werden. Background: Chronic conjunctivitis and keratoconjunctivitis account for a significant ocular morbidity. Early diagnosis and appropriate management are essential to avoid persisting structural damage and visual loss. In children, the correct diagnosis is frequently delayed because of the low individual experience with pediatric ocular inflammation, the uncommon clinical manifestations and the rarity of some conditions. This study aims to identify the problems associated with the diagnosis of chronic pediatric (kerato-)conjunctivitis. Patients and Methods: 48 consecutive tertiary referrals (median age: 8.5 years) with chronic conjunctivitis or keratoconjunctivitis were studied. The ocular inflammation of all patients was denoted by their referring ophthalmologists as “chronic conjunctivitis refractory to therapy”. The median time since disease onset was 23 months (range: 3 - 118). On average, 2.8 (range: 2 - 5) ophthalmologists were seen before the final diagnosis was made. A standardized protocol was used to classify and diagnose the ocular inflammation. Laboratory investigations were carried out to confirm the diagnosis in 20 out of 48 patients. Results: In 33 out of 48 patients treatment failure was due to an inappropriate diagnosis. The most frequent diagnosis were Staphylococcus-associated inflammation (n = 21) and vernal keratoconjunctivitis (n = 12). Viral infection causing molluscum contagiosum was the most frequent condition that was missed (n = 7). Ligneous conjunctivitis (n = 2) was not recognised by the 9 ophthalmologists who were previously in charge of the treatment. Significant corneal involvement was found in 24 (50 %) patients. Conclusion: History taking and a thorough clinical examination of the entire ocular surface allow the correct diagnosis of and therapy for chronic surface inflammation in almost all pediatric patients. Subtle clinical changes have to be sought actively to avoid misdiagnosis. Such changes include lesions in the anterior lid margin, collarettes, follicules, papillae, and superficial punctate keratopathy.
- 16 May 2006
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 223 (5) , 353-356
Therapierefraktäre chronische (Kerato-)Conjunctivitis bei Kindern
Hintergrund: Chronische (Kerato-)Conjunctivitiden verursachen eine erhebliche okuläre Morbidität. Durch eine frühzeitige Diagnostik und korrekte Behandlung können strukturelle Schäden der Augenoberfläche und damit auch Sehstörungen vermieden werden. Bei Kindern kommt es nicht selten zu verschleppten Verläufen infolge geringer individueller Erfahrung des behandelnden Arztes, ungewöhnlicher klinischer Manifestationen und der Seltenheit einzelner Krankheitsbilder. Diese Studie untersucht die Probleme, die bei der Diagnostik der chronischen (Kerato-)Conjunctivitis im Kindesalter auftreten. Patienten und Methoden: 48 Patienten, die von niedergelassenen Ophthalmologen zur weiteren Abklärung einer therapierefraktären chronischen Conjunctivitis zugewiesen worden waren, wurden untersucht. Der Altersmeridian lag bei 8,5 Jahren, die mediane Erkrankungsdauer betrug 23 Monate (3 - 118). Durchschnittlich wurden 2,8 Augenärzte konsultiert, bevor die Diagnostik abgeschlossen wurde. Die klinischen Befunde wurden mit einem standardisierten Protokoll erfasst und analysiert. Bei 20 von 48 Patienten wurde die klinische Diagnose durch Laborbefunde bestätigt. Ergebnisse: Bei 33 von 48 Patienten stand der therapierefraktäre Verlauf mit einer ungenügenden Diagnostik in Zusammenhang. Die häufigsten Diagnosen waren „Staphylokokkenproblematik” (n = 21) und „Keratoconjunctivitis vernalis” (n = 12). Am häufigsten wurde die Diagnose einer Infektion mit Molluscum-contagiosum-Virus verpasst (n = 7). Die Conjunctivitis lignosa (n = 2) wurde von 9 Voruntersuchern verkannt. Eine klinisch relevante Hornhautbeteiligung fand sich bei insgesamt 24 Patienten (50 %). Schlussfolgerung: Eine präzise Anamnese und minutiöse Untersuchung der gesamten Augenoberfläche ermöglichen praktisch ausnahmslos eine korrekte diagnostische Einstufung und Therapie von chronisch entzündlichen Oberflächenerkrankungen im Kindesalter. Nach gewissen diagnostischen Schlüsselbefunden wie warzigen Veränderungen am anterioren Lidrand, Collerettes, Follikeln, Papillen und speziellen Stippungsmustern der Hornhaut muss aktiv gesucht werden. Background: Chronic conjunctivitis and keratoconjunctivitis account for a significant ocular morbidity. Early diagnosis and appropriate management are essential to avoid persisting structural damage and visual loss. In children, the correct diagnosis is frequently delayed because of the low individual experience with pediatric ocular inflammation, the uncommon clinical manifestations and the rarity of some conditions. This study aims to identify the problems associated with the diagnosis of chronic pediatric (kerato-)conjunctivitis. Patients and Methods: 48 consecutive tertiary referrals (median age: 8.5 years) with chronic conjunctivitis or keratoconjunctivitis were studied. The ocular inflammation of all patients was denoted by their referring ophthalmologists as “chronic conjunctivitis refractory to therapy”. The median time since disease onset was 23 months (range: 3 - 118). On average, 2.8 (range: 2 - 5) ophthalmologists were seen before the final diagnosis was made. A standardized protocol was used to classify and diagnose the ocular inflammation. Laboratory investigations were carried out to confirm the diagnosis in 20 out of 48 patients. Results: In 33 out of 48 patients treatment failure was due to an inappropriate diagnosis. The most frequent diagnosis were Staphylococcus-associated inflammation (n = 21) and vernal keratoconjunctivitis (n = 12). Viral infection causing molluscum contagiosum was the most frequent condition that was missed (n = 7). Ligneous conjunctivitis (n = 2) was not recognised by the 9 ophthalmologists who were previously in charge of the treatment. Significant corneal involvement was found in 24 (50 %) patients. Conclusion: History taking and a thorough clinical examination of the entire ocular surface allow the correct diagnosis of and therapy for chronic surface inflammation in almost all pediatric patients. Subtle clinical changes have to be sought actively to avoid misdiagnosis. Such changes include lesions in the anterior lid margin, collarettes, follicules, papillae, and superficial punctate keratopathy.
- 1 May 2006
- Published by Springer Nature in Der Ophthalmologe
- Vol. 103 (5) , 416-417
Phosphate in ophthalmologischen Präparaten
- 1 May 2006
- Published by Springer Nature in Der Ophthalmologe
- Vol. 103 (5) , 416-417
Phosphate in ophthalmologischen Präparaten
- 1 March 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (3) , 285-288
Corneal calcification following intensified treatment with sodium hyaluronate artificial tears
Aim: To report a potential adverse effect of intensified treatment with sodium hyaluronate artificial tears. Methods: Five cases of deep calcium deposition in the cornea associated with ocular surface disease and frequent use of hyaluronic acid artificial tears are described. All patients used one formulation of phosphate buffered hyaluronate eye drops when rapid calcification developed. All eyes required corneal graft surgery for visual rehabilitation. Specimens at keratoplasty were available for light microscopy and investigation by dispersive x ray analysis. The phosphate concentration in the medication used for topical treatment was measured and compared to alternative hyaluronate preparations. Results: Light microscopy showed dense mineralisation of the entire stroma. The crystalline deposits consisted of hydroxyapatite, Ca5(PO4)3OH. A 50-fold higher concentration of phosphate was measured in the sodium hyaluronate eye drops used for treatment (50.9 mmol/l) when compared with normal serum. The other hyaluronate formulations showed phosphate concentrations from Conclusions: The hyaluronate artificial tear formulation “Hylo-Comod” favours the formation of insoluble crystalline calcium phosphate deposits in presence of epithelial keratopathy. This is because of its high phosphate concentration and typically frequent instillation. Manufacturers and prescribers should be aware that topical preparations may contain considerable amounts of phosphate which may lead to sight threatening corneal complications.
- 1 March 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (3) , 285-288
Corneal calcification following intensified treatment with sodium hyaluronate artificial tears
Aim: To report a potential adverse effect of intensified treatment with sodium hyaluronate artificial tears. Methods: Five cases of deep calcium deposition in the cornea associated with ocular surface disease and frequent use of hyaluronic acid artificial tears are described. All patients used one formulation of phosphate buffered hyaluronate eye drops when rapid calcification developed. All eyes required corneal graft surgery for visual rehabilitation. Specimens at keratoplasty were available for light microscopy and investigation by dispersive x ray analysis. The phosphate concentration in the medication used for topical treatment was measured and compared to alternative hyaluronate preparations. Results: Light microscopy showed dense mineralisation of the entire stroma. The crystalline deposits consisted of hydroxyapatite, Ca5(PO4)3OH. A 50-fold higher concentration of phosphate was measured in the sodium hyaluronate eye drops used for treatment (50.9 mmol/l) when compared with normal serum. The other hyaluronate formulations showed phosphate concentrations from Conclusions: The hyaluronate artificial tear formulation “Hylo-Comod” favours the formation of insoluble crystalline calcium phosphate deposits in presence of epithelial keratopathy. This is because of its high phosphate concentration and typically frequent instillation. Manufacturers and prescribers should be aware that topical preparations may contain considerable amounts of phosphate which may lead to sight threatening corneal complications.